ncam fitc antibody Search Results


anti cd56 stained nk92 cells  (Miltenyi Biotec)
95
Miltenyi Biotec anti cd56 stained nk92 cells
CD301-CARs display specific cytotoxicity against osteosarcoma cell lines. ( A ) Schematic representation of the CD301 LEC-CAR: ( B ) Expression of CD301 CAR at the cell surface of <t>NK92</t> cells. NK92 cells were retrovirally transduced and sorted based on the GFP expression. The expression of the CD301 CAR construct was measured by flow cytometry using an antibody specific to the CD301 CRD. Color denotes areas of high and low population density. ( C ) Detection of CD301 ligands on target cells: osteosarcoma cell lines were stained with fluorescently labeled recombinant CD301 and analyzed by flow cytometry. ( D ) Cytotoxicity assay: NK92 cells expressing the CD301-CAR were cocultured for 3 h with calcein-labeled target cells with an effector-to-target ratio of 3:1 and 5:1, respectively, and measured as quadruplicates. Columns represent the median. Error bars show standard deviation. p < 0.01 is indicated by **, respectively.
Anti Cd56 Stained Nk92 Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd56 stained nk92 cells/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
anti cd56 stained nk92 cells - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
anti human monoclonal cd56 ncam1 fitc conjugated  (Miltenyi Biotec)
94
Miltenyi Biotec anti human monoclonal cd56 ncam1 fitc conjugated
CD301-CARs display specific cytotoxicity against osteosarcoma cell lines. ( A ) Schematic representation of the CD301 LEC-CAR: ( B ) Expression of CD301 CAR at the cell surface of <t>NK92</t> cells. NK92 cells were retrovirally transduced and sorted based on the GFP expression. The expression of the CD301 CAR construct was measured by flow cytometry using an antibody specific to the CD301 CRD. Color denotes areas of high and low population density. ( C ) Detection of CD301 ligands on target cells: osteosarcoma cell lines were stained with fluorescently labeled recombinant CD301 and analyzed by flow cytometry. ( D ) Cytotoxicity assay: NK92 cells expressing the CD301-CAR were cocultured for 3 h with calcein-labeled target cells with an effector-to-target ratio of 3:1 and 5:1, respectively, and measured as quadruplicates. Columns represent the median. Error bars show standard deviation. p < 0.01 is indicated by **, respectively.
Anti Human Monoclonal Cd56 Ncam1 Fitc Conjugated, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human monoclonal cd56 ncam1 fitc conjugated/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
anti human monoclonal cd56 ncam1 fitc conjugated - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
cd56  (Miltenyi Biotec)
94
Miltenyi Biotec cd56
Mononuclear cell and soluble factor profiles at the time of laparoscopy.
Cd56, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd56/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
cd56 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
ncam-fitc  (Becton Dickinson)
90
Becton Dickinson ncam-fitc
Mononuclear cell and soluble factor profiles at the time of laparoscopy.
Ncam Fitc, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ncam-fitc/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
ncam-fitc - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cd56 antibody  (Proteintech)
93
Proteintech cd56 antibody
Mononuclear cell and soluble factor profiles at the time of laparoscopy.
Cd56 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd56 antibody/product/Proteintech
Average 93 stars, based on 1 article reviews
cd56 antibody - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


CD301-CARs display specific cytotoxicity against osteosarcoma cell lines. ( A ) Schematic representation of the CD301 LEC-CAR: ( B ) Expression of CD301 CAR at the cell surface of NK92 cells. NK92 cells were retrovirally transduced and sorted based on the GFP expression. The expression of the CD301 CAR construct was measured by flow cytometry using an antibody specific to the CD301 CRD. Color denotes areas of high and low population density. ( C ) Detection of CD301 ligands on target cells: osteosarcoma cell lines were stained with fluorescently labeled recombinant CD301 and analyzed by flow cytometry. ( D ) Cytotoxicity assay: NK92 cells expressing the CD301-CAR were cocultured for 3 h with calcein-labeled target cells with an effector-to-target ratio of 3:1 and 5:1, respectively, and measured as quadruplicates. Columns represent the median. Error bars show standard deviation. p < 0.01 is indicated by **, respectively.

Journal: International Journal of Molecular Sciences

Article Title: Glycan Structures in Osteosarcoma as Targets for Lectin-Based Chimeric Antigen Receptor Immunotherapy

doi: 10.3390/ijms25105344

Figure Lengend Snippet: CD301-CARs display specific cytotoxicity against osteosarcoma cell lines. ( A ) Schematic representation of the CD301 LEC-CAR: ( B ) Expression of CD301 CAR at the cell surface of NK92 cells. NK92 cells were retrovirally transduced and sorted based on the GFP expression. The expression of the CD301 CAR construct was measured by flow cytometry using an antibody specific to the CD301 CRD. Color denotes areas of high and low population density. ( C ) Detection of CD301 ligands on target cells: osteosarcoma cell lines were stained with fluorescently labeled recombinant CD301 and analyzed by flow cytometry. ( D ) Cytotoxicity assay: NK92 cells expressing the CD301-CAR were cocultured for 3 h with calcein-labeled target cells with an effector-to-target ratio of 3:1 and 5:1, respectively, and measured as quadruplicates. Columns represent the median. Error bars show standard deviation. p < 0.01 is indicated by **, respectively.

Article Snippet: The degranulation of NK92 CAR and wild-type NK92 cells was induced upon interaction with target cells at an E:T ratio of 1:1 for 4 h at 37 °C and was assessed by measuring the expression of CD107a with a PE/Cy7-labeled anti-CD107a antibody (Biolegend, #328617) at the surface of FITC-labeled anti-CD56-stained NK92 cells (Miltenyi, #130-114-740).

Techniques: Expressing, Construct, Flow Cytometry, Staining, Labeling, Recombinant, Cytotoxicity Assay, Standard Deviation

Lytic activity of CD301-CAR-expressing NK92 cells correlates with interferon-gamma secretion and increased degranulation. ( A ) CAR expression leads to enhanced interferon-gamma secretion of NK92 cells upon engagement with osteosarcoma cell lines. ( B ) CAR expression leads to enhanced degranulation of NK92 cells upon engagement with osteosarcoma cells. Columns represent the mean of three independent experiments measured in triplicates. Error bars show the standard deviation of the mean. p < 0.05, p < 0.01, and p < 0.001 are indicated by *, **, or *** respectively.

Journal: International Journal of Molecular Sciences

Article Title: Glycan Structures in Osteosarcoma as Targets for Lectin-Based Chimeric Antigen Receptor Immunotherapy

doi: 10.3390/ijms25105344

Figure Lengend Snippet: Lytic activity of CD301-CAR-expressing NK92 cells correlates with interferon-gamma secretion and increased degranulation. ( A ) CAR expression leads to enhanced interferon-gamma secretion of NK92 cells upon engagement with osteosarcoma cell lines. ( B ) CAR expression leads to enhanced degranulation of NK92 cells upon engagement with osteosarcoma cells. Columns represent the mean of three independent experiments measured in triplicates. Error bars show the standard deviation of the mean. p < 0.05, p < 0.01, and p < 0.001 are indicated by *, **, or *** respectively.

Article Snippet: The degranulation of NK92 CAR and wild-type NK92 cells was induced upon interaction with target cells at an E:T ratio of 1:1 for 4 h at 37 °C and was assessed by measuring the expression of CD107a with a PE/Cy7-labeled anti-CD107a antibody (Biolegend, #328617) at the surface of FITC-labeled anti-CD56-stained NK92 cells (Miltenyi, #130-114-740).

Techniques: Activity Assay, Expressing, Standard Deviation

Combination of immune checkpoint inhibition with CD301 CAR immunotherapy. ( A ) Flow cytometry analysis showing the surface expression of the TIGIT and PVRIG on NK92 cells. Respective antibody staining is shown as a red histogram, and the isotype control and unstained control are depicted as blue and gray histograms. ( B ) Target cell expression of PVR and PVRL2. Expression was analyzed by flow cytometry. The binding of anti-PVR and anti-PVRL2 antibodies are shown as orange histograms. The isotype and unstained control are shown as blue and gray histograms. ( C ) Cytotoxicity assay: NK92 cells expressing the CD301-CAR were cocultured for 3 h with calcein-labeled targets with an effector target ratio of 3:1, respectively, in the presence or absence of different amounts of the inhibitory anti-TIGIT antibody. Measurements were performed as quadruplicates. Columns represent the mean of three independent experiments. Error bars show the standard deviation of the mean. p < 0.05 and p < 0.01 are indicated by * and **, respectively.

Journal: International Journal of Molecular Sciences

Article Title: Glycan Structures in Osteosarcoma as Targets for Lectin-Based Chimeric Antigen Receptor Immunotherapy

doi: 10.3390/ijms25105344

Figure Lengend Snippet: Combination of immune checkpoint inhibition with CD301 CAR immunotherapy. ( A ) Flow cytometry analysis showing the surface expression of the TIGIT and PVRIG on NK92 cells. Respective antibody staining is shown as a red histogram, and the isotype control and unstained control are depicted as blue and gray histograms. ( B ) Target cell expression of PVR and PVRL2. Expression was analyzed by flow cytometry. The binding of anti-PVR and anti-PVRL2 antibodies are shown as orange histograms. The isotype and unstained control are shown as blue and gray histograms. ( C ) Cytotoxicity assay: NK92 cells expressing the CD301-CAR were cocultured for 3 h with calcein-labeled targets with an effector target ratio of 3:1, respectively, in the presence or absence of different amounts of the inhibitory anti-TIGIT antibody. Measurements were performed as quadruplicates. Columns represent the mean of three independent experiments. Error bars show the standard deviation of the mean. p < 0.05 and p < 0.01 are indicated by * and **, respectively.

Article Snippet: The degranulation of NK92 CAR and wild-type NK92 cells was induced upon interaction with target cells at an E:T ratio of 1:1 for 4 h at 37 °C and was assessed by measuring the expression of CD107a with a PE/Cy7-labeled anti-CD107a antibody (Biolegend, #328617) at the surface of FITC-labeled anti-CD56-stained NK92 cells (Miltenyi, #130-114-740).

Techniques: Inhibition, Flow Cytometry, Expressing, Staining, Control, Binding Assay, Cytotoxicity Assay, Labeling, Standard Deviation

Mononuclear cell and soluble factor profiles at the time of laparoscopy.

Journal: Cells

Article Title: Altered Monocyte and Lymphocyte Phenotypes Associated with Pathogenesis and Clinical Efficacy of Progestogen Therapy for Peritoneal Endometriosis in Adolescents

doi: 10.3390/cells13141187

Figure Lengend Snippet: Mononuclear cell and soluble factor profiles at the time of laparoscopy.

Article Snippet: The monocyte markers included conditionally M2 anti-inflammatory (CD206, CD163) and M1 pro-inflammatory (CD86, CD80) characteristics of monocytes and macrophages: CD206 (130-095-131; Miltenyi Biotec), CD86 (130-116-160; Miltenyi Biotec), CD16 (A07766; Beckman Coulter, Brea, CA, USA), CD80 (130-117-683; Miltenyi Biotec), CD163 (130-097-630; Miltenyi Biotec), CD56 (130-113-871; Miltenyi Biotec), CD192 (130-118-338; Miltenyi Biotec) and HLA-DR (130-111-789; Miltenyi Biotec).

Techniques: Comparison

One-year progestogen therapy-related dynamics of mononuclear cell and soluble factor profiles in adolescents with peritoneal endometriosis (PE).

Journal: Cells

Article Title: Altered Monocyte and Lymphocyte Phenotypes Associated with Pathogenesis and Clinical Efficacy of Progestogen Therapy for Peritoneal Endometriosis in Adolescents

doi: 10.3390/cells13141187

Figure Lengend Snippet: One-year progestogen therapy-related dynamics of mononuclear cell and soluble factor profiles in adolescents with peritoneal endometriosis (PE).

Article Snippet: The monocyte markers included conditionally M2 anti-inflammatory (CD206, CD163) and M1 pro-inflammatory (CD86, CD80) characteristics of monocytes and macrophages: CD206 (130-095-131; Miltenyi Biotec), CD86 (130-116-160; Miltenyi Biotec), CD16 (A07766; Beckman Coulter, Brea, CA, USA), CD80 (130-117-683; Miltenyi Biotec), CD163 (130-097-630; Miltenyi Biotec), CD56 (130-113-871; Miltenyi Biotec), CD192 (130-118-338; Miltenyi Biotec) and HLA-DR (130-111-789; Miltenyi Biotec).

Techniques: